Immuno-oncology innovator receives life science people’s choice award
SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 (GLOBE NEWSWIRE) — BioInformatics Inc., the leading research and advisory firm serving the life science tool market, today announced Fluidigm as the Company to Watch in 2019 at the biannual Life Science Industry Awards® (LSIA).
Designed as people’s choice awards, LSIA has been a tradition in the life science industry for 15 years. Recipients are selected based on responses from thousands of scientists who are members of The Science Advisory Board, the world’s largest market research panel of scientific customers. Winners are chosen based on both the number of votes received and the depth of the company’s customer loyalty and satisfaction.
“We are excited to recognize Fluidigm as the Company to Watch in 2019,” said Craig Overpeck, CEO of BioInformatics Inc. “Fluidigm is demonstrating impressive momentum, exemplified by the recent introduction of the Hyperion™ Imaging System for high‑definition tissue imaging. Their innovative solutions for immuno-oncology research have ignited significant interest within our community and have the potential to revolutionize this important field for many years to come.”
“It is an honor to receive this LSIA award,” said Chris Linthwaite, President and CEO of Fluidigm. “We have made significant progress in empowering our customers with industry-leading technologies to uncover meaningful insights in health and disease, with an emphasis on immunology, cancer and immuno-oncology research. The impact these researchers are making with our mass cytometry and microfluidics technologies has been truly impressive. Together with them, we envision a bright future ahead.”
About Bioinformatics Inc.
BioInformatics Inc., now part of Science and Medicine Group, is the premier research and advisory firm serving the life science, clinical diagnostics, and analytical instrument industries. By leveraging our expert network of more than 50,000 life scientists, the company has supported more than 500 companies in creating insights that lead to better business decisions. Offerings include assessing the size and attractiveness of scientific markets, optimizing product configurations and pricing, validating corporate acquisitions, measuring customer loyalty, and evaluating brand strength and positioning.
About Fluidigm Corporation
Fluidigm (NASDAQ:FLDM) develops, manufactures, and markets life science analytical and preparatory systems for markets such as mass cytometry, high-throughput genomics, and single‑cell genomics. We sell to leading academic institutions, clinical research laboratories, and pharmaceutical, biotechnology, and agricultural biotechnology companies worldwide. Our systems are based on proprietary microfluidics and multiparameter mass cytometry technology and are designed to significantly simplify experimental workflow, increase throughput, and reduce costs while providing excellent data quality. Fluidigm products are provided for Research Use Only. Not for use in diagnostic procedures.
We use our website (www.fluidigm.com), corporate Twitter account (@fluidigm), Facebook page (https://www.facebook.com/fluidigm), and LinkedIn page (https://www.linkedin.com/company/fluidigm-corporation) as channels of distribution of information about our products, our planned financial and other announcements, our attendance at upcoming investor and industry conferences, and other matters. Such information may be deemed material information, and we may use these channels to comply with our disclosure obligations under Regulation FD. Therefore, investors should monitor our website and our social media accounts in addition to following our press releases, SEC filings, public conference calls, and webcasts.
Fluidigm, the Fluidigm logo, and Hyperion are trademarks and/or registered trademarks of Fluidigm Corporation in the United States and/or other countries. All other trademarks are the sole property of their respective owners.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, among others, statements regarding the potential impact of Fluidigm products on translational research. Forward-looking statements are subject to numerous risks and uncertainties that could cause actual results to differ materially from currently anticipated results, including but not limited to risks relating to challenges inherent in developing, manufacturing, launching, marketing, and selling new products; the uncertain regulatory environment; potential product performance and quality issues; intellectual property risks; competition; and interruptions or delays in the supply of components or materials for, or manufacturing of, Fluidigm products. Information on these and additional risks and uncertainties and other information affecting Fluidigm business and operating results are contained in Fluidigm’s Annual Report on Form 10-K for the year ended December 31, 2017, and in its other filings with the Securities and Exchange Commission, including Fluidigm’s Quarterly Report on Form 10-Q for the quarter ended September 30, 2018. These forward-looking statements speak only as of the date hereof. Fluidigm disclaims any obligation to update these forward-looking statements except as may be required by law.
Contacts:
BioInformatics Inc.
Monika Mahajani
Content Marketing Associate
703 778 3080 x37
m.mahajani@bioinfoinc.com
Fluidigm
Media:
Michaeline Bunting
Senior Director, Marketing
650 737 4190
michaeline.bunting@fluidigm.com
Investors:
Agnes Lee
Vice President, Investor Relations
650 416 7423
agnes.lee@fluidigm.com